Compare AGM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | BEAM |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1995 | 2019 |
| Metric | AGM | BEAM |
|---|---|---|
| Price | $223.70 | $29.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $215.00 | $50.75 |
| AVG Volume (30 Days) | 81.4K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | 1.09 | ★ 82.31 |
| EPS | ★ 10.15 | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | $33.77 |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $136.57 | $16.03 |
| 52 Week High | $248.29 | $38.26 |
| Indicator | AGM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 53.83 |
| Support Level | $166.64 | $28.40 |
| Resistance Level | $240.49 | $34.20 |
| Average True Range (ATR) | 5.52 | 1.36 |
| MACD | -2.21 | 0.46 |
| Stochastic Oscillator | 33.78 | 66.66 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.